How does QSP modeling support R&D decisions? Case examples of modeling impact in central nervous system and inflammatory diseases.
Presented at the AAPS PharmSci360 Conference, November 2019
Investigating GPR119 agonist efficacy in a systems pharmacology model of diabetes
Presented by Sanofi and Rosa at the American Conference on Pharmacometrics (ACoP), October 2019
Leveraging a Diabetes QSP Model to Drive Decisions in Target ID and Validation for a Proinsulin Program
Presented by Merck and Rosa at the American Conference on Pharmacometrics (ACoP), October 2019
Development of a mechanistic representation of a stable solid tumor
Presented by Rosa at the American Conference on Pharmacometrics (ACoP), October 2019
A qualitative and quantitative framework to assess the value of QSP modeling in pharmaceutical development.
Presented by Rosa at the American Conference on Pharmacometrics (ACoP), October 2019
Using QSP modeling to support pediatric drug development: case studies in bile acids and immuno-oncology
Presented at the American Conference on Pharmacometrics (ACoP), October 2019
A simulation study for clinical efficacy of an anti ORAI1 antibody (DS 2741a) on atopic dermatitis using QSP modeling for preclinical to clinical translation
Presented by Daiichi Sankyo and Rosa at the 28th European Academy of Dermatology and Venereology (EADV) Congress (2019)
Evaluation of competitive differentiation of novel therapies and the impact of patient variability on efficacy in a psoriasis QSP platform
Presented by Sanofi and Rosa at at the Population Approach Group in Europe Conference (PAGE), 2019
A Flexible Approach for Context‐Dependent Assessment of Quantitative Systems Pharmacology Models
Published in CPT: Pharmacometrics & Systems Pharmacology, Apr. 14, 2019.
Considerations for Adapting Pre-existing Mechanistic Quantitative Systems Pharmacology Models for New Research Contexts
Published in Frontiers in Pharmacology, Apr. 18, 2019.
Incorporation of Renal SGLT Function into a Quantitative Systems Pharmacology (QSP) Model
Presented by Sanofi and Rosa at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) conference, 2019.
Evaluation of Novel Anti-TNFα and IL-6R Therapies in a Rheumatoid Arthritis (RA) Quantitative Systems Pharmacology (QSP) Platform
Presented by Sanofi and Rosa at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) conference, 2019.
